Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Operating Leases data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 16.64% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 16.64% YoY), and the FY2025 full-year result was $2.4 million, down 15.65% from the prior year.
• Operating Leases for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.1 million in Q1 2022 and bottomed at $2.2 million in Q1 2026.
• The 5-year median for Operating Leases is $3.1 million (2024), against an average of $3.1 million.
• The widest annual swing landed in 2022, when Operating Leases changed 0.0%; it then decreased 17.39% in 2023.
• A 5-year view of Operating Leases shows it stood at $3.6 million in 2022, then decreased by 10.37% to $3.2 million in 2023, then dropped by 12.61% to $2.8 million in 2024, then declined by 15.65% to $2.4 million in 2025, then dropped by 4.89% to $2.2 million in 2026.
• The last three Operating Leases figures came in at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.

Peer Comparison